Financial Performance - The company's operating revenue for Q1 2023 was ¥2,660,096,706.22, representing a year-on-year increase of 4.59%[6] - Net profit attributable to shareholders of the listed company decreased by 60.38% to ¥5,420,341.81 compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥6,086,080.64, a decrease of 169.54% year-on-year[6] - Basic and diluted earnings per share were both ¥0.003, down 62.50% from the previous year[6] - The company reported a net loss of CNY 601,083,049.19 for Q1 2023, slightly improved from a net loss of CNY 606,503,391.00 in Q1 2022[27] - The net profit for Q1 2023 was CNY 6,546,123.55, a decrease of 66.0% compared to CNY 19,196,750.52 in Q1 2022[31] - Operating profit for Q1 2023 was CNY 36,450,940.95, down 11.8% from CNY 41,184,658.02 in the same period last year[31] - The total operating profit for Q1 2023 was CNY 18,931,965.78, compared to CNY 68,174,477.62 in Q1 2022, reflecting a significant decrease[46] - The net profit for Q1 2023 was CNY 21,339,797.92, down from CNY 64,533,832.18 in the same period last year[46] Cash Flow - The net cash flow from operating activities increased significantly by 404.11% to ¥187,858,742.38, mainly due to an increase in cash collections[6] - Cash flow from operating activities netted CNY 187,858,742.38 in Q1 2023, a significant increase from CNY 37,265,495.04 in Q1 2022[36] - The total amount of cash received from operating activities was CNY 2,055,067,700.88, while cash paid for goods and services was CNY 825,897,402.46 in Q1 2023[36] - The net cash flow from financing activities was CNY 308,525,208.29, a significant improvement from a negative cash flow of CNY -667,914,386.06 in the previous year[38] - The net cash flow from financing activities improved to CNY 106,704,458.19 in Q1 2023, compared to a negative CNY 961,604,887.43 in Q1 2022[49] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥21,819,916,060.13, an increase of 2.82% from the end of the previous year[9] - Total assets reached CNY 21,819,916,060.13 as of March 31, 2023, compared to CNY 21,221,017,906.40 at the end of 2022, marking a growth of 2.8%[25] - Total liabilities increased to CNY 15,585,239,520.50 in Q1 2023 from CNY 14,992,641,818.84 in Q4 2022, reflecting a rise of 3.9%[26] - The total liabilities amounted to CNY 11,991,449,739.57, compared to CNY 11,693,543,754.40 in the previous year, indicating a rise in financial obligations[44] Equity - The equity attributable to shareholders of the listed company was ¥5,305,299,999.21, a slight increase of 0.10% compared to the end of the previous year[9] - The total equity attributable to shareholders was CNY 5,305,299,999.21 as of March 31, 2023, compared to CNY 5,300,125,328.88 at the end of 2022, showing a marginal increase of 0.1%[27] - The total equity increased to CNY 6,790,179,729.59 from CNY 6,768,839,931.67, reflecting a growth in shareholder value[44] Operating Costs and Expenses - Total operating costs for Q1 2023 were CNY 2,624,501,680.17, up from CNY 2,498,274,235.59 in Q1 2022, reflecting a year-over-year increase of 5.0%[27] - Research and development expenses increased significantly to CNY 66,514,021.08 in Q1 2023, up 99.5% from CNY 33,337,722.55 in Q1 2022[31] - Research and development expenses for Q1 2023 were CNY 13,324,018.64, significantly higher than CNY 4,374,035.32 in Q1 2022, indicating increased investment in innovation[44] - The company incurred financial expenses of CNY 131,734,667.63 in Q1 2023, down from CNY 142,638,164.40 in Q1 2022, a reduction of 7.0%[31] - The company reported a decrease in financial expenses to CNY 85,675,989.61 from CNY 109,874,458.68, indicating better cost management[44] Inventory and Receivables - Accounts receivable increased to CNY 2,397,251,350.19 in Q1 2023 from CNY 2,231,066,181.09 in Q4 2022, indicating a rise of 7.5%[22] - Inventory as of March 31, 2023, was CNY 2,565,609,361.14, slightly up from CNY 2,523,301,463.29 at the end of 2022, showing an increase of 1.7%[22] - The company's inventory increased to CNY 1,233,877,392.97 from CNY 1,136,776,702.39, reflecting a growth of approximately 8.5% year-over-year[38]
华北制药(600812) - 2023 Q1 - 季度财报